Payment overview · 2025
General Payments
$339.02
20 reported records · 7 companies
Healthcare provider profile · identity verified
Hemantkumar G Patel, MD
Allopathic & Osteopathic Physicians|General Practice · NEWARK, NJ · NPI 1932178357
Verified facts
What the public records show
CMS Open Payments records show Hemantkumar G Patel, MD received $339.02 in general payments during 2025 across 20 reported records.
Insmed, Inc. accounted for 52.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Biktarvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 684 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insmed, Inc. | Unresolved — no canonical attribution shown | $176.94 | 52.2% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.99 | 20.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.98 | 6.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.96 | 5.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.87 | 5.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.99 | 5.3% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $15.29 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $339.02 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $176.94 | 11 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $61.46 | 4 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $33.21 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
684 | 111 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1102 | 302 |
| Amlodipine Besylate | Amlodipine Besylate | 880 | 239 |
| Eliquis | Apixaban | 684 | 111 |
| Furosemide | Furosemide | 397 | 123 |
| Losartan Potassium | Losartan Potassium | 364 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 355 | 118 |
| Carvedilol | Carvedilol | 326 | 79 |
| Gabapentin | Gabapentin | 315 | 80 |
| Levetiracetam | Levetiracetam | 313 | 56 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 306 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 299 | 78 |
| Metformin Hcl | Metformin Hcl | 290 | 94 |
| Tamsulosin Hcl | Tamsulosin Hcl | 283 | 71 |
| Metoprolol Tartrate | Metoprolol Tartrate | 254 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 237 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 199 | 60 |
| Divalproex Sodium | Divalproex Sodium | 197 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 196 | 64 |
| Mirtazapine | Mirtazapine | 191 | 43 |
| Trazodone Hcl | Trazodone Hcl | 186 | 50 |
| Quetiapine Fumarate | Quetiapine Fumarate | 167 | 36 |
| Lisinopril | Lisinopril | 165 | 45 |
| Potassium Chloride | Potassium Chloride | 153 | 51 |
| Latanoprost | Latanoprost | 145 | 33 |
| Enoxaparin Sodium | Enoxaparin Sodium | 139 | 20 |
| Sertraline Hcl | Sertraline Hcl | 136 | 24 |
| Donepezil Hcl | Donepezil Hcl | 135 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 65 |
| Famotidine | Famotidine | 126 | 36 |
| Clonidine Hcl | Clonidine Hcl | 125 | 35 |
| Risperidone | Risperidone | 120 | 25 |
| Azithromycin | Azithromycin | 113 | 84 |
| Januvia | Sitagliptin Phosphate | 109 | 20 |
| Omeprazole | Omeprazole | 109 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 106 | 40 |
| Entresto | Sacubitril/Valsartan | 99 | 22 |
| Clozapine | Clozapine | 96 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 32 |
| Nifedipine Er | Nifedipine | 94 | 26 |
| Insulin Lispro | Insulin Lispro | 90 | 37 |
| Heparin Sodium | Heparin Sodium,porcine | 87 | 15 |
| Simvastatin | Simvastatin | 87 | 27 |
| Ibuprofen | Ibuprofen | 80 | 36 |
| Memantine Hcl | Memantine Hcl | 79 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 77 | 11 |
| Midodrine Hcl | Midodrine Hcl | 75 | 27 |
| Lactulose | Lactulose | 74 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 25 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 73 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 67 | 14 |
| Spironolactone | Spironolactone | 66 | 15 |
| Jardiance | Empagliflozin | 62 | 14 |
| Scopolamine | Scopolamine | 61 | 11 |
| Montelukast Sodium | Montelukast Sodium | 60 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 57 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 12 |
| Finasteride | Finasteride | 56 | 18 |
| Glimepiride | Glimepiride | 56 | 21 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 56 | suppressed |
| Prednisone | Prednisone | 55 | 23 |
| Promethazine Hcl | Promethazine Hcl | 53 | 35 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 50 | suppressed |
| Levofloxacin | Levofloxacin | 49 | 42 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | suppressed |
| Allopurinol | Allopurinol | 46 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | 15 |
| Methylprednisolone | Methylprednisolone | 46 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 15 |
| Risperdal Consta | Risperidone Microspheres | 42 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 42 | 17 |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 41 | 13 |
| Silver Sulfadiazine | Silver Sulfadiazine | 41 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 28 |
| Humalog | Insulin Lispro | 38 | 14 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 38 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 12 |
| Enalapril Maleate | Enalapril Maleate | 37 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | 23 |
| Labetalol Hcl | Labetalol Hcl | 36 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 35 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 35 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 33 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 33 | suppressed |
| Meloxicam | Meloxicam | 33 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 33 | suppressed |
| Enulose | Lactulose | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 23 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | 15 |
| Oxcarbazepine | Oxcarbazepine | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | 19 |
| Ammonium Lactate | Ammonium Lactate | 29 | 17 |
| Glipizide | Glipizide | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 15 |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 28 | suppressed |
| Ketoconazole | Ketoconazole | 28 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Amantadine | Amantadine Hcl | 26 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 26 | suppressed |
| Haloperidol | Haloperidol | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | 13 |
| Ssd | Silver Sulfadiazine | 26 | 11 |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Budesonide | Budesonide | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | 12 |
| Alogliptin | Alogliptin Benzoate | 23 | suppressed |
| Clonidine | Clonidine | 23 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 23 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 11 |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 17 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 21 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Acetylcysteine | Acetylcysteine | 20 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 20 | suppressed |
| Nystatin | Nystatin | 20 | 13 |
| Sucralfate | Sucralfate | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 18 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | 12 |
| Tivicay | Dolutegravir Sodium | 18 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 17 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Ritonavir | Ritonavir | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Naproxen | Naproxen | 16 | 13 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 16 | 12 |
| Admelog Solostar | Insulin Lispro | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Darunavir | Darunavir | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 11 |
| Restasis | Cyclosporine | 15 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Acamprosate Calcium | Acamprosate Calcium | 13 | suppressed |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 13 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | 11 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Abacavir-Lamivudine | Abacavir Sulfate/Lamivudine | 11 | suppressed |
| Ampicillin Sodium | Ampicillin Sodium | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Procrit | Epoetin Alfa | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $339.02 · 20 records | Insmed, Inc. | Arikayce, BREZTRI, Brinsupri, FASENRA, LOKELMA, NUCALA, REXULTI, VYNDAQEL, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error